# Core B: Biospecimens

> **NIH NIH P50** · UNIVERSITY OF IOWA · 2021 · $258,840

## Abstract

ABSTRACT: Core B: Biospecimens. The UI/MC SPORE Biospecimens Shared Resource provides a 
coordinated, centralized, and dedicated core for the procurement, processing and annotation of biospecimens 
from patients with lymphoma. The goal of the Biospecimens Core is to procure a variety of biologic 
specimens on all patients involved in UI/MC SPORE clinical trials and all newly diagnosed lymphoma patients 
seen at the UI Holden Comprehensive Cancer Center (HCCC) and the Mayo Clinic Cancer Center (MCCC) 
and enrolled into the Molecular Epidemiology Resource (MER). The specific aims of the Core are: Aim 1) To 
provide accurate classification of all lymphomas (including chronic lymphocytic leukemia/small lymphocytic 
lymphoma) from patients enrolled onto SPORE clinical trials and the MER; Aim 2) To collect, process, bank 
and distribute biologic specimens from Iowa and Mayo lymphoma patients for translational research; Aim 3) To 
track all biospecimens and ensure linkage to clinical, outcome and related data; and Aim 4) To provide 
expertise, collaborative support and service for full Projects and Career Enhancement/Developmental 
Research Awardee research. Specimens are collected and processed under rigorous quality control and 
distributed to researchers or banked for future SPORE projects. Activities are tracked using a sophisticated 
database that merges activities at Iowa and Mayo and allows integration with clinical and other data collected 
in research projects. The Core provides specialized expertise in working with lymphoma biospecimens and is 
closely aligned with institutional research cores and shared resources, but does not duplicate them. The Core 
has been highly productive in the last funding cycle and since its inception in 2002. To date, the Core has 
supported the pathology review and specimen collection from patients on all SPORE clinical trials; 7065 
patients enrolled into the MER, and 1237 patients from those outside of the MER eligibility criteria (e.g., 
relapsed or transformed cases). The entire collection consists of 7958 germline DNA and 5733 serum 
samples; assembled tissue microarrays in 1790 patients; and banked frozen cells on 1284 patients. New in 
this funding period, we developed a process to collect stool for gut microbiome analysis, and have collected 
samples from 153 patients and 47 matched household controls. Also new to the Core is time-of-flight mass 
cytometry (CyTOF), which allows simultaneous evaluation of >35 proteins on a single-cell level. In planning the 
next grant cycle, we have worked with all 4 new Projects to ensure that we can meet their biospecimen needs. 
In addition, the Core will work with young investigators in the Career Enhancement Program on the research 
design of their proposals so that the appropriate samples can be provided. Lastly, we will provide 
biospecimens expertise and biobank resources for innovative Developmental Research Proposals. These 
goals will be met by judicious use of ...

## Key facts

- **NIH application ID:** 10208774
- **Project number:** 5P50CA097274-20
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Sergei Syrbu
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $258,840
- **Award type:** 5
- **Project period:** 2002-09-11 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10208774

## Citation

> US National Institutes of Health, RePORTER application 10208774, Core B: Biospecimens (5P50CA097274-20). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10208774. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*